Companies › Beijing InnoCare Pharma Tech
11 active drug programs in 60 registered trials: 43 Phase 2, 9 Phase 1, 6 Phase 3, 2 Phase 4; Oncology, Other, Immunology, Hematology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ICP-332 Spleen tyrosine kinase (SYK) inhibitor | FYN | Phase 3 | Atopic Dermatitis; Prurigo Nodularis (PN); Plaque Psoriasis; Chronic Spontaneous Urticaria (CSU) … | Nov 2026 |
| ICP-488 | – | Phase 3 | Plaque Psoriasis Patients; Cutaneous Lupus Erythematosus (CLE) | Feb 2027 |
| Lenalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | DLBCL | Apr 2027 |
| Orelabrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Relapsed/Refractory Marginal Zone Lymphoma; Hematologic Malignancies; Part 1:r/r B-cell Malignancies; OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma … | Aug 2028 |
| ICP-192 FGFR2 inhibitor | FGFR2 | Phase 2 | Intrahepatic Cholangiocarcinoma (ICC) | Dec 2026 |
| ICP-248 BTK inhibitor | – | Phase 2 | Relapsed or Refractory Mantle Cell Lymphoma (MCL); Hematologic Malignancies; Hematological Malignancies; Acute Myelogenous Leukemia | Jun 2027 |
| CM355 | – | Phase 1 | Hematoma | Dec 2026 |
| ICP-723 | – | Phase 1 | Advanced Solid Tumors Harboring NTRK Fusion; Solid Tumors | Dec 2027 |
| ICP-B208 | – | Phase 1 | Advanced Solid Tumor | Dec 2030 |
| CM369 | – | Phase 1 | Advanced Solid Tumors and Hematologic Malignancies | – |
| ICP-538 | – | Phase 1 | Health Services Research | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05728658 | ICP-248 | Phase 1 | Hematological Malignancies | Oncology | Aug 2025 |
| NCT05690581 | CM369 | Phase 1 | Advanced Solid Tumors and Hematologic Malignancies | Oncology | Oct 2025 |
| NCT04014205 | Orelabrutinib | Phase 1 | Part 1:r/r B-cell Malignancies | Oncology | Jun 2026 |
| NCT07535099 | ICP-538 | Phase 1 | Health Services Research | Other | Sep 2026 |
| NCT06775860 | ICP-332 | Phase 3 | Atopic Dermatitis | Immunology | Nov 2026 |
| NCT06701357 | Orelabrutinib | Phase 2 | DLBCL | Oncology | Dec 2026 |
| NCT05678270 | ICP-192 | Phase 2 | Intrahepatic Cholangiocarcinoma (ICC) | Oncology | Dec 2026 |
| NCT05209620 | Orelabrutinib | Phase 2 | Central Nervous System Lymphoma | Oncology | Dec 2026 |
| NCT05210868 | CM355 | Phase 1 | Hematoma | Other | Dec 2026 |
| NCT05933967 | Orelabrutinib | Phase 2 | The First Affiliated Hospital of Nanchang University | Other | Dec 2026 |
| NCT06134284 | Orelabrutinib | Phase 4 | OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma | Oncology | Dec 2026 |
| NCT04961515 | Orelabrutinib | Phase 2 | Primary Central Nervous System Hodgkin Lymphoma | Oncology | Dec 2026 |
| NCT06842199 | ICP-488 | Phase 3 | Plaque Psoriasis Patients | Immunology | Feb 2027 |
| NCT07453368 | Orelabrutinib | Phase 2 | Autoimmune Hemolytic Anemia (AIHA) | Hematology | Mar 2027 |
| NCT06647940 | Orelabrutinib | Phase 2 | Diffuse Large B Cell Lymphoma (DLBCL) | Oncology | Mar 2027 |
| NCT07236099 | ICP-332 | Phase 2 | Prurigo Nodularis (PN) | Immunology | Mar 2027 |
| NCT07440537 | ICP-488 | Phase 2 | Cutaneous Lupus Erythematosus (CLE) | Immunology | Mar 2027 |
| NCT07559331 | Orelabrutinib | Phase 3 | Primary Immune Thrombocytopenia (ITP) | Hematology | Apr 2027 |
| NCT05552937 | Lenalidomide | Phase 2 | DLBCL | Oncology | Apr 2027 |
| NCT07251998 | ICP-332 | Phase 2 | Plaque Psoriasis | Immunology | May 2027 |
| NCT06656494 | ICP-248 | Phase 1 | Acute Myelogenous Leukemia | Oncology | Jun 2027 |
| NCT06513234 | Orelabrutinib | Phase 2 | Marginal Zone Lymphoma | Oncology | Jun 2027 |
| NCT07680933 | Orelabrutinib | Phase 2 | DLBCL - Diffuse Large B Cell Lymphoma | Oncology | Jun 2027 |
| NCT06504940 | Orelabrutinib | Phase 2 | Marginal Zone Lymphoma | Oncology | Jul 2027 |
| NCT06496308 | Orelabrutinib | Phase 3 | Mantle Cell Lymphoma (MCL) | Oncology | Jul 2027 |
| NCT07022223 | Orelabrutinib | Phase 2 | Marginal Zone Lymphoma(MZL) | Oncology | Sep 2027 |
| NCT06583837 | Orelabrutinib | Phase 2 | Lymphoma, B-Cell, Marginal Zone | Oncology | Sep 2027 |
| NCT07355699 | Orelabrutinib | Phase 4 | Marginal Zone Lymphoma(MZL) | Oncology | Sep 2027 |
| NCT06700798 | Orelabrutinib | Phase 2 | Marginal Zone Lymphoma(MZL) | Oncology | Dec 2027 |
| NCT07082686 | ICP-248 | Phase 2 | Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Oncology | Dec 2027 |
| NCT07441993 | Orelabrutinib | Phase 2 | Marginal Zone Lymphoma | Oncology | Dec 2027 |
| NCT05745623 | ICP-723 | Phase 1 | Advanced Solid Tumors Harboring NTRK Fusion | Oncology | Dec 2027 |
| NCT07247383 | Orelabrutinib | Phase 2 | Marginal Zone Lymphoma of Ocular Adnexal | Oncology | Dec 2027 |
| NCT05600660 | Orelabrutinib | Phase 2 | Primary Central Nervous System Lymphoma | Oncology | Dec 2027 |
| NCT06985472 | Orelabrutinib | Phase 2 | Initial MZL | Oncology | Dec 2027 |
| NCT07499271 | Orelabrutinib | Phase 2 | Diffuse Large B-Cell Lymphoma (DLBCL) | Oncology | Dec 2027 |
| NCT07448324 | Orelabrutinib | Phase 2 | Marginal Zone Lymphoma(MZL) | Oncology | Jan 2028 |
| NCT06228963 | Orelabrutinib | Phase 2 | MALT Lymphoma of Stomach | Oncology | Jan 2028 |
| NCT04685226 | ICP-723 | Phase 1 | Solid Tumors | Oncology | Jan 2028 |
| NCT07554898 | Orelabrutinib | Phase 2 | MALT Lymphoma | Oncology | Feb 2028 |
| NCT07372365 | Orelabrutinib | Phase 2 | Marginal Zone Lymphoma (MZL) | Oncology | Apr 2028 |
| NCT06454968 | Orelabrutinib | Phase 2 | Marginal Zone Lymphoma | Oncology | Jun 2028 |
| NCT07208981 | Orelabrutinib | Phase 2 | Marginal Zone Lymphoma(MZL) | Oncology | Jun 2028 |
| NCT07199296 | Orelabrutinib | Phase 2 | Mantle Cell Lymphoma (MCL) | Oncology | Jul 2028 |
| NCT06566807 | Orelabrutinib | Phase 2 | Marginal Zone Lymphoma | Oncology | Aug 2028 |
| NCT04989621 | Orelabrutinib | Phase 2 | Follicular Lymphoma | Oncology | Aug 2028 |
| NCT06082102 | Orelabrutinib | Phase 3 | Relapsed/Refractory Marginal Zone Lymphoma | Oncology | Aug 2028 |
| NCT07272499 | Orelabrutinib | Phase 2 | Mantle Cell Lymphoma (MCL) | Oncology | Sep 2028 |
| NCT07378527 | ICP-332 | Phase 2 | Chronic Spontaneous Urticaria (CSU) | Immunology | Sep 2028 |
| NCT06521255 | Lenalidomide | Phase 3 | DLBCL | Oncology | Sep 2028 |
| NCT07185373 | Orelabrutinib | Phase 2 | Primary Central Nervous System Lymphoma | Oncology | Sep 2028 |
| NCT06503276 | Orelabrutinib | Phase 2 | Extranodal Marginal Zone B-cell Lymphoma | Oncology | Oct 2028 |
| NCT06793189 | Orelabrutinib | Phase 2 | Marginal Zone Lymphoma(MZL) | Oncology | Dec 2028 |
| NCT07410520 | Orelabrutinib | Phase 2 | Primary Central Nervous System Lymphoma (PCNSL) | Oncology | Dec 2028 |
| NCT07078500 | Orelabrutinib | Phase 2 | Diffuse Large B-Cell Lymphoma (DLBCL) | Oncology | Dec 2028 |
| NCT07047612 | ICP-332 | Phase 2 | Non Segmental Vitiligo | Immunology | Apr 2029 |
| NCT07719556 | Orelabrutinib | Phase 2 | Mantle Cell Lymphoma (MCL) | Oncology | Jul 2029 |
| NCT06378138 | ICP-248 | Phase 2 | Hematologic Malignancies | Oncology | Nov 2030 |
| NCT06378138 | Orelabrutinib | Phase 2 | Hematologic Malignancies | Oncology | Nov 2030 |
| NCT07617493 | ICP-B208 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2030 |
Bristol-Myers Squibb Roche BeOne Medicines Incyte Shandong New Time Pharmaceutical CellCentric AstraZeneca Sanofi Eli Lilly Johnson & Johnson (Janssen)
Jiangsu Hansoh Pharmaceutical Incyte Akeso Dizal Pharmaceuticals Taiho Oncology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.